Re: Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study

Re: Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study

Bibliographic Details
Main Author:	Tayyar Alp Özkan
Format:	Article
Language:	English
Published:	Galenos Yayinevi 2015-12-01
Series:	Journal of Urological Surgery
Online Access:	http://jurolsurgery.org/article_10110/Re-Predicting-High-grade-Cancer-At-Ten-core-Prostate-Biopsy-Using-Four-Kallikrein-Markers-Measured-In-Blood-In-The-Protect-Study

Similar Items

Re: Transperineal Template-Guided Prostate Biopsy: 10 Years of Experience
by: Tayyar Alp Özkan
Published: (2015-09-01)

Re: A Statewide Intervention to Reduce Hospitalizations after Prostate Biopsy
by: Tayyar Alp Özkan
Published: (2015-09-01)

Re: Exosomal Lncrna-P21 Levels May Help to Distinguish Prostate Cancer from Benign Disease
by: Tayyar Alp Özkan
Published: (2015-12-01)

Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study.
by: Burton, A, et al.
Published: (2013)

Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.
by: Vickers, A, et al.
Published: (2010)

Prostate kallikrein markers in diagnosis, risk stratification and prognosis.
by: Ulmert, D, et al.
Published: (2009)

Prostate Testing for Cancer and Treatment (ProtecT) feasibility study
by: J. Donovan, et al.
Published: (2003-01-01)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: Prospective evaluation within ProtecT study
by: Rosario, D, et al.
Published: (2012)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study
by: Rosario, D, et al.
Published: (2012)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study.
by: Rosario, D, et al.
Published: (2012)

A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands.
by: Gupta, A, et al.
Published: (2010)

Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study
by: Adams, Charleen D., et al.
Published: (2018)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden.
by: Vickers, A, et al.
Published: (2008)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden
by: Scardino Peter T, et al.
Published: (2008-07-01)

Mortality among nen with advanced prostate cancer excluded from the ProtecT Trial
by: Johnston, T, et al.
Published: (2016)

The Prostate Testing for Cancer and Treatment (ProtecT) study: what have we learnt?
by: Hamdy, F
Published: (2017)

The ProtecT trial - Evaluating the effectiveness of treatment for clinically localised prostate cancer (ISRCTN20141297)
by: Lane, J, et al.
Published: (2004)

Prostate volume predicts high grade prostate cancer both in digital rectal examination negative (ct1c) and positive (≥ct2) patients
by: Hasan Yilmaz, et al.
Published: (2014-10-01)

The protecT (prostate testing for cancer and treatment) study: Evaluating screening and treatment of clinically localised prostate cancer in the UK
by: Hamdy, F, et al.
Published: (2006)

Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study.
by: Catto, J, et al.
Published: (2011)

Suitability of PSA-detected localised prostate cancers for focal therapy: Experience from the ProtecT study
by: Catto, J, et al.
Published: (2011)

Prostate cancer screening and management: Caution against over-interpreting the results of the latest study, ProtecT
by: Isaac Yi Kim
Published: (2023-07-01)

Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the protecT randomised controlled trial according to treatment received
by: Neal, D, et al.
Published: (2019)

Ten-core versus 16-core transrectal ultrasonography guided prostate biopsy for detection of prostatic carcinoma: a prospective comparative study in Indian population
by: V. Surya Prakash, et al.
Published: (2013-12-01)

A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France.
by: Benchikh, A, et al.
Published: (2010)

A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France
by: Villers Arnauld, et al.
Published: (2010-11-01)

Alcohol consumption and PSA-detected prostate cancer risk--a case-control nested in the ProtecT study.
by: Zuccolo, L, et al.
Published: (2013)

Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies.
by: Lane, J, et al.
Published: (2010)

Breast carcinoma grading on core needle biopsy – to grade or not to grade?
by: Joanna Szpor, et al.
Published: (2023-10-01)

Expression of kallikrein-related peptidase 7 is decreased in prostate cancer
by: Chong-Yu Zhang, et al.
Published: (2015-02-01)

Gleason grading of prostate cancer in needle core biopsies: a comparison of general and urologic pathologists
by: Jaudah Ahmed Al-Maghrabi, et al.
Published: (2013-01-01)

Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study.
by: Rosario, D, et al.
Published: (2008)

Serum total prostate-specific antigen (tPSA): correlation with diagnosis and grading of prostate cancer in core needle biopsy
by: Nina Čamdžić, et al.
Published: (2021-02-01)

Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
by: Haese, A, et al.
Published: (2003)

Total and gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies
by: Haese, A, et al.
Published: (2003)

He protec but he also attac – Inflammasomes swinging the sword
by: Aila Akosua Kattner
Published: (2023-10-01)

A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.
by: Vickers, A, et al.
Published: (2010)

Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.
by: Christensson, A, et al.
Published: (2011)

Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: The ProtecT three-arm RCT
by: Hamdy, FC, et al.
Published: (2020)

Association of obesity with prostate cancer: A case-control study within the population-based PSA testing phase of the ProtecT study
by: Dimitropoulou, P, et al.
Published: (2011)